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OBJECTIVES The aim of our study was to assess whether acute, short-term hyperglycemia affects platelet
reactivity in patients with Type II diabetes mellitus (T2DM).
BACKGROUND Hyperglycemic spikes are thought to precipitate ischemic events in T2DM. Previous studies
have shown in vivo platelet activation in diabetes; however, no studies have assessed whether
acute in vivo hyperglycemia induces further activation of platelets.
METHODS In a cross-over, randomized, double-blind study, 12 patients with T2DM underwent 4 h of
either acute hyperglycemia (13.9 mmol/l, 250 mg/dl) or euglycemia (5.5 mmol/l, 100 mg/dl).
Shear stress-induced platelet activation, P-selectin and lysosomal integral membrane protein
(LIMP) expression on platelets in the bleeding-time blood, urinary 11-dehydro-thromboxane
B2 (TxB2) excretion, von Willebrand factor:antigen (vWF:Ag), and von Willebrand factor:
activity (vWF:activity) were measured before and after hyperglycemia or euglycemia.
RESULTS Shear stress-induced platelet activation, P-selectin and LIMP expression on platelets in the
bleeding-time blood, and urinary 11-dehydro-TxB2 excretion increased significantly after
hyperglycemic clamping, whereas no changes were observed after euglycemic clamping.
Plasma vWF:Ag and vWF:activity increased strikingly in parallel fashion after hyperglycemic
clamping, whereas no changes were observed after euglycemic clamping.
CONCLUSIONS Our data demonstrate that acute, short-term hyperglycemia induces an increased activation of
platelets exposed to high shear stress conditions in vitro (filtration method) or in vivo
(bleeding time). In vivo platelet activation is reflected by an increased urinary excretion of
11-dehydro-TxB2. The increased levels of vWF in the circulation correlate with the increase
in platelet activation markers and may indicate some degree of causation. Acute, short-term
hyperglycemia in T2DM may precipitate vascular occlusions by facilitating platelet
activation. (J Am Coll Cardiol 2003;41:1013–20) © 2003 by the American College of
Cardiology Foundation
Compared with non-diabetics, patients with Type II dia-
betes mellitus (T2DM) have a two- to four-fold increased
risk of ischemic cardiovascular disease, a risk largely inde-
pendent of concomitant hypertension, hypercholesterol-
emia, and smoking (1–3). Increased platelet reactivity has
been suggested as a potential mechanism of the accelerated
atherosclerosis and enhanced incidence of arterial thrombo-
sis seen in diabetics (4,5).
Several in vitro studies have shown hyper-reactivity of
platelets from T2DM patients, as indicated by enhanced
aggregation, increased fibrinogen binding, and thrombox-
ane production (6–8). However, the pathophysiologic rel-
evance of in vitro aggregometric tests to the involvement of
platelets in the in vivo atherothrombotic complications of
diabetes is questionable (5).
More interesting, enhanced biosynthesis of throm-
boxane A2 by platelets has been shown in vivo in T2DM, by
the measurement of urinary excretion of 11-dehydro-
thromboxane B2 (TxB2) (8).
Enhanced in vivo aggregation in diabetics is a conse-
quence of a metabolic alteration and not of large-vessel
arterial disease (9). Indeed, tight glycemic control is asso-
ciated with a clear reduction of in vivo platelet activation
(8,10).
The correlation between fasting plasma glucose and the
incidence of cardiovascular events is well established (2,3),
but several clues point to an important role of hyperglycemic
spikes in determining atherosclerotic complications (11) and
in precipitating ischemic events (12,13).
However, at present, no conclusive data on the effect of a
hyperglycemic spike on platelet activation in vivo in diabet-
ics are available. High shear stress-induced platelet activa-
tion is crucial in determining the thrombotic complications
occurring at an arterial site of atherosclerotic narrowing
(14–16), and plasma von Willebrand factor (vWF) plays an
important role in these phenomena. Shear-induced platelet
adhesion and aggregation on subendothelium are increased
in diabetic patients under good metabolic control (17), and
abnormalities of vWF have been described in diabetes (18).
The aim of our study was to establish whether acute,
short-term hyperglycemia, in the range of that commonly
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seen in diabetics in the post-prandial condition, induces
platelet hyper-reactivity in patients with T2DM, with
particular reference to parameters of platelet function rele-
vant to the pathophysiology of arterial thrombotic compli-
cations.
METHODS
Subjects. Twelve patients with T2DM (7 males and 5
females; age 60  2 years [range 48 to 68]; duration of
diabetes 7  1 years; body mass index 29  0.5 kg/m2), as
defined in accordance with the American Diabetes Associ-
ation criteria (19), were studied on two separate occasions.
They had not ingested any drugs interfering with platelet
function within the previous 10 days and were studied in the
morning, under fasting conditions. None had a history of
ischemic cardiovascular disease, but the physical examina-
tion or instrumental diagnosis was positive for macrovascu-
lar complications. At the time of the study, they were being
treated with diet (n  5), oral hypoglycemic agents (met-
formin and/or sulfonylureas) (n  5), or insulin (n  2).
None had a history of hemorrhagic diathesis or abnormal-
ities of platelets, renal failure, hepatic failure, alcohol abuse,
or heart valve stenosis.
Study design. The patients were enrolled in a cross-over,
randomized, double-blind study to assess the effects of 4 h
of controlled hyperglycemia or euglycemia on platelet func-
tion, using the glucose clamp technique, as previously
described (20). The patients underwent the two clamp
procedures, according to a randomized sequence, 7 to 10
days apart. The study was approved by our institutional
Board Review Committee, and written, informed consent
was given by all patients. In the hyperglycemic study,
glucose was infused at a variable rate, based on plasma
glucose measured every 5 min, to maintain steady state
glucose at 250 mg/dl (139 mmol/l). In the euglycemic study,
insulin was infused at the rate of 0.4 mU/kg per min, and
glucose was infused at a variable rate to maintain plasma
glucose at 100 mg/dl (5.5 mmol/l) (20).
Plasma glucose was measured by means of a Beckman
glucose analyzer (Glucose Analyzer II, Beckman Instru-
ments, Fullerton, California). Plasma insulin was measured
by a previously described assay (21). Glycosylated hemoglo-
bin A1c (HbA1c) was determined by high-performance
liquid chromatography, using the HI-Auto A1c TM HA
8121 apparatus (DIC, Kyoto Daiichi, Kogaku Co., Ltd.,
Kyoto, Japan) (range in non-diabetic subjects: 3.8% to 5.5%).
Blood was collected before and at the end of each clamp.
A bleeding-time test was carried out before pre-clamp blood
sampling, and another bleeding-time test was done after
post-clamp blood sampling. All laboratory tests were carried
out by investigators who were unaware of the type of
clamping procedure.
Bleeding time. A standardized bleeding-time test was
performed using an automatic template device (Simplate II,
Organon Teknika Corp., Jessup, Maryland; batch no.
102985), as previously described (22,23). The mean bleed-
ing time was calculated from the two cuts. The blood
emerging from the skin wound inflicted for the measure-
ment of the bleeding time was collected for platelet activa-
tion measurements (23).
Platelet activation studies. Shear-induced platelet activa-
tion was assessed with the O’Brien filtration test (24,25).
Two aliquots (5 ml each) of citrated venous whole blood
were pushed through polycarbonate glass fiber filters (Pall
U100, batch no. 53503; Pall Corp., Port Washington, New
York), at a constant pressure of 40 mm Hg. The filter closure
time and percentage of platelets retained were measured.
In particular, platelets retained between 20 and 40 s were
calculated by the difference of the counts in the blood that
had flowed through the filter between 20 and 40 s from the
start of the test and the counts in the blood before it passed
through the filter.
Platelet aggregation induced by adenosine diphosphate
(ADP) 2 mol/l was performed as previously described
(22,26), and the maximal amplitude of aggregation was
recorded at 3 min. Spontaneous platelet aggregation was
assessed as described (27).
Flow cytometric analysis of platelets was carried out in
samples from peripheral venous blood and in the whole
blood emerging from the bleeding-time wounds, as previ-
ously described (23), by assessing the expression on the
platelet surface of the activation antigens P-selectin and
LIMP. Expression of activation antigens is given as the
percentage of platelets positively stained with the monoclo-
nal antibodies of interest (23).
Von Willebrand factor measurements. Plasma obtained
by centrifugation of citrated venous blood at 3,000g for 20
min was immediately frozen and stored at 80°C for later
assay.
Levels of vWf:antigen (Ag) were measured with an
enzyme-linked immunosorbent assay kit (Asserachrom
vWF, Boehringer Mannheim, Mannheim, Germany),
whereas vWF: activity was tested with a system (vWF
Activity Kit, Shield Diagnostic Ltd., Dundee, U.K.; kindly
provided by Dr. Poggesi, Bouty S.p.A., Milan, Italy) that
utilizes a monoclonal antibody recognizing an epitope of
vWF involved in the interaction with glycoprotein Ib-alpha.
The results are expressed as the percentage of control.
Urinary excretion of 11-dehydro-TxB2. The urinary ex-
cretion of 11-dehydro-TxB2 was evaluated by a radioimmu-
Abbreviations and Acronyms
ADP  adenosine diphosphate
Ag  antigen
AUC  area under the curve
HbA1c  glycosylated hemoglobin
LIMP  lysosomal integral membrane protein
T2DM  Type II diabetes mellitus
TxB2  thromboxane B2
vWF  von Willebrand factor
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noassay, as previously described (9). Briefly, urine sub-
samples (40 ml) were taken from the 24-h urine collection
ending at the start of the clamp (pre-samples), from the 4-h
urine collection of the clamp (acute samples), and from the
24-h urine collection starting from the moment of the
beginning of the clamp (post-samples) and then snap-
frozen in liquid nitrogen and stored at 80°C until assay.
Immunoreactive 11-dehydro-TxB2 was assessed by pre-
viously gas chromatography–mass spectrometry-validated
radioimmunoassay techniques (8,28). Plasma glucose, insu-
lin, and HbA1c were measured by standard techniques (20).
Statistical analysis. Statistical analysis was carried out
according to the method of Jones and Kenword (29) for
crossover designs with two baselines, as previously described
(30). Only after carryover and direct-by-period effects were
shown as not significant, thus confirming the adequacy of
the washout period, data were analyzed with repeated
measures analysis of variance followed by Tukey’s multiple
comparisons test. For the correlation between different
parameters, data from each time point of the single patients
were analyzed as separate observations by the Pearson first
degree index. Cumulative in situ platelet activation during
the bleeding-time procedure was calculated as the area
under the curve (AUC) by the trapezoidal rule, using data of
P-selectin and LIMP expression on platelets up to the third
minute, and interpolating them by the GraphPad-Prism 2
software. Statistical analysis and correlation studies were
performed using the GraphPad-Prism 2 package. Data are
expressed as the mean value  SEM. Differences were
considered as significant at p  0.05.
RESULTS
Patients. The metabolic and blood count characteristics of
the patients are reported in Table 1. The HbA1c levels
before euglycemic and hyperglycemic clamping were similar
(7.2  0.18% and 7.2  0.16%, respectively; p  NS).
Fasting plasma glucose levels were also similar before the
two clamps, with values of 140  7 mg/dl (7.8  0.4
mmol/l) and 141  6 mg/dl (7.8  0.3 mmol/l), with
comparable metabolic conditions at baseline on the two
study days. Baseline plasma insulin was also similar on the
two study days (7.4  0.9 and 7.4  0.9 U/ml). In the
euglycemic study, plasma glucose between 30 and 240 min
was 98 2 mg/dl (5.4 0.1 mmol/l; coefficient of variation
4.5  0.1%), whereas it was 249  3 mg/dl (13.8  0.2
mmol/l) with the hyperglycemic clamp (coefficient of vari-
ation 5.1 0.2%). The glucose infusion rate was 4.35 0.4
mg/kg per min during hyperglycemic clamping and 3.8 
0.6 mg/kg per min during euglycemic clamping (p  0.05).
Plasma insulin between 30 and 240 min was 53  1.5
U/ml during euglycemic clamping and 51.3  3.5 U/ml
during hyperglycemic clamping (p  NS).
Platelet counts were also similar before the euglycemic
and hyperglycemic clamps (181  5.2 and 177  6.4 
109/l, respectively) and were slightly but significantly re-
duced after clamping (177  6.2 and 169  6.9  109/l,
respectively; p  0.01 vs. pre-clamp).
The hematocrit values were 38.9  0.9% and 38.1 
0.8% before the euglycemic and hyperglycemic clamps,
respectively, and were slightly but not significantly reduced
after clamping (37.8 0.8% and 37.3 0.6%, respectively).
Bleeding time. The bleeding time at baseline was similar
to that before the euglycemic and hyperglycemic clamps
(368  33 and 360  34 s, respectively). It tended to be
shortened after the euglycemic clamp, but not significantly
(340  25 s, p  NS), whereas it was significantly
shortened after the hyperglycemic clamp (275  20 s, p 
0.0007). All values, before and after the clamps, were within
normal ranges (138 to 570 s).
Shear-induced platelet activation. Shear stress-induced
platelet activation was similar at baseline on the two study
days (filter closure time: 49.2  2.2 and 49.2  1.9 s;
retained platelets: 81.6 1.5% and 81.9 3.5%, before the
euglycemic and hyperglycemic clamps, respectively).
Shear-induced platelet activation was unaffected by the
euglycemic clamp (filter closure time: 48.3  1.8 s, p  NS
vs. pre-clamp; retained platelets: 81.2  1.4%, p  NS vs.
pre-clamp). In contrast, after the hyperglycemic clamp, it
was enhanced (filter closure time: 42.5  1.9 s, p  0.0012;
retained platelets: 87.1  3.2%, p  0.0002) (Fig. 1).
Platelet aggregometry. Platelet aggregation induced by
ADP was similar at baseline before the two clamps and did
not change significantly after either. Transmittance was
78.4  6.6% and 77.3  7.9% before euglycemic and
hyperglycemic clamping and 81  6.3% and 79.8  6.6%
after these clamps, respectively. Spontaneous platelet aggre-
gation was not observed in any of the patients either before
or after the euglycemic and hyperglycemic clamps.
Table 1. Metabolic and Blood Count Characteristics of Patients Before and After the
Glycemic Clamps
Parameter
Before/After
p ValueEuglycemia Hyperglycemia
HbA1c (%) 7.2  0.18 7.2  0.16 NS
Fasting plasma glucose (mmol/l) 7.8  0.4/5.4  0.1* 7.8  0.3/13.8  0.2* NS/p  0.05
Plasma insulin (U/ml) 7.4  0.9/53  1.5* 7.4  0.9/51.3  3.5* NS/NS
Platelet count (109/l) 181  5.2/177  6.2* 177  6.4/169  6.9* NS/p  0.05
Hematocrit (%) 38.9  0.9/37.8  0.8 38.1  0.8/37.3  0.6 NS/NS
*Significantly different from “before” value. Data are presented as the mean value  SEM.
HbA1c  glycosylated hemoglobin.
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Flow cytometry. PLATELET ACTIVATION MARKERS IN VE-
NOUS BLOOD. P-selectin expression on platelets circulating
in venous blood was similar at baseline on the two study
days (7.9  1.6% and 7.5  1.9% positive cells, respective-
ly). These values are somewhat higher than the average
values found in healthy controls in our laboratory (4.0 
0.5% positive cells).
P-selectin expression on platelets did not change signif-
icantly after either the euglycemic or hyperglycemic clamp
(6.6  1.2% and 8.5  1.8%, respectively, p  NS).
Expression of LIMP on platelets circulating in venous
blood was similar at baseline on the two study days (9.1 
1.9% and 7.5 1.9% positive cells, respectively). Also, these
values were somewhat higher than those found in healthy
controls in our laboratory (7.0  0.3%). Expression of
LIMP on platelets did not change significantly after either
the euglycemic or hyperglycemic clamp (9.7 2.1% and 8.2
 2%, respectively; p  NS).
PLATELET ACTIVATION MARKERS IN BLEEDING-TIME
BLOOD. At baseline, before the clamps, the expression of
P-selectin on platelets in the blood emerging from the
bleeding-time wound increased progressively up to the
fourth minute, in a comparable way on both study days,
compatible with ongoing platelet activation, as previously
reported (23,31). A maximum of 80.6  10.3% and 78.3 
2.15% of P-selectin–positive platelets was reached before
euglycemic or hyperglycemic clamping, respectively (data
not shown).
After the euglycemic clamp, the time-dependent rise in
P-selectin expression on platelets in shed blood was similar
to that observed before the clamp, whereas after the hyper-
glycemic clamp, it was considerably greater, with a signifi-
cantly larger increase starting from the second minute (Fig.
2A).
Similarly, at baseline, the expression of LIMP on platelets
in the blood emerging from the bleeding-time wound
increased progressively up to the fourth minute, compatible
with ongoing platelet activation, as previously reported
(23,31), reaching a maximum of 64.4  4.4% and 63.7 
5.9% of positive platelets before the euglycemic and hyper-
glycemic clamps, respectively (data not shown).
After the euglycemic clamp, the rise in LIMP expression
on platelets in the bleeding-time blood was similar to that
observed before the clamp, whereas after the hyperglycemic
clamp, it was greater, with a significantly larger increase
starting from the second minute (Fig. 2B).
Determinations of vWF. Von Willebrand factor antigen
in plasma at baseline was similar before the euglycemic and
hyperglycemic clamps (93.8  12.8% and 100.4  10.5%,
Figure 1. Shear stress-induced platelet activation before and after the euglycemic and hyperglycemic clamps. (A) Filter closure time (s). (B) Platelets
retained between 20 and 40 s (% of total). #p  0.0012 vs. hyper-pre (i.e., before hyperglycemic clamp). §p  0.002 vs. hyper-pre. Eu  euglycemic clamp.
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respectively; p  NS) and not substantially different from
the average normal values found in our laboratory (98.4 
2.3%). After the hyperglycemic clamp, vWF:Ag increased
to 144.3  14% (p  0.002), whereas after the euglycemic
clamp, it did not change (98.2  11.4%, p  NS).
The vWF:activity at baseline was also comparable before
the two clamp studies (71.7  7.2% and 81.9  6.7%,
respectively; p  NS) and increased markedly after the
hyperglycemic clamp, reaching 124.5  17.3% (p  0.04),
whereas it was unchanged after the euglycemic clamp (82.3
 14.3%).
Urinary 11-dehydro-TxB2. Basal urinary 11-dehydro-
TxB2 excretion before the clamps was comparable on the
two study days (1,274  223 and 1,357  301 pg/mg
creatinine before the euglycemic and hyperglycemic clamps,
respectively), and it was higher than the values of healthy
controls in our laboratory (150 to 450 pg/mg creatinine).
Urinary 11-dehydro-TxB2 excretion was unchanged during
euglycemic clamping (1,140  248 pg/mg creatinine, p 
NS), whereas it was significantly increased during hypergly-
cemic clamping (1,878  376 pg/mg creatinine, p  0.02).
Finally, 11-dehydro-TxB2 during the 24 h after the clamp
procedure did not differ significantly on the two study days
(1,080  201 pg/mg creatinine after the euglycemia clamp
and 1,296  269 pg/mg creatinine after the hyperglycemic
clamp, p  NS).
Correlations. Plasma vWF:Ag and vWF:activity showed a
highly significant correlation. A statistically significant cor-
relation was found between plasma vWF:activity and shear-
induced platelet activation (filter closure time), between
vWF:activity and urinary 11-dehydro-TxB2 excretion dur-
ing the clamps, and between vWF:activity and the AUC of
P-selectin and LIMP expression in bleeding-time blood
(Fig. 3).
Figure 2. Platelet activation in bleeding-time blood before and after the euglycemic and hyperglycemic clamps. (A) P-selectin expression on platelets.
(B) Expression of LIMP on platelets. Open bars euglycemic; striped bars hyperglycemic. Data are reported as the percent increase in positive platelets
between samples after versus before clamping. *p 0.04, §p 0.02 vs. before clamping. **p 0.004, #p 0.03 vs. before clamping, ##p 0.005 vs. before
clamping.
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A statistically significant correlation was also found be-
tween 11-dehydro-TxB2 excretion and P-selectin expres-
sion on platelets in the bleeding-time blood (AUC) (Fig. 3).
No correlations were found between vWF:activity and
ADP-induced platelet aggregation or P-selectin and LIMP
expression on platelets in venous blood (data not shown).
Figure 3. Correlations between different parameters. (A) Correlation between vWF:activity and vWF:Ag (r  0.84, p  0.0001). (B) Correlation between
vWF:activity and shear stress-induced platelet activation (filter closure time) (r  0.32, p  0.02). (C) Correlation between vWF:activity and P-selectin
(P-Sel) expression on platelets in bleeding-time blood (AUC) (r  0.36, p  0.03). (D) Correlation between vWF:activity and LIMP expression on
platelets in bleeding-time blood (AUC) (r  0.34, p  0.02). (E) Correlation between vWF:activity and urinary 11-dehydro-TxB2 excretion during
clamping (r  0.34, p  0.03). (F) Correlation between urinary 11-dehydro-TxB2 excretion during clamping and P-selectin expression on platelets in
bleeding-time blood (AUC) (r  0.37, p  0.02). Ct  creatinine.
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DISCUSSION
Platelet activation and cardiovascular complications in
T2DM. Previous studies, including data from our group,
have demonstrated in vivo platelet activation and platelet
hyper-reactivity in T2DM patients (6–10), and chronic
hyperglycemia has been clearly identified as a causal factor
(8–10). Although the reduction of platelet hyper-reactivity
following maintenance of tight metabolic control in diabet-
ics has been demonstrated (8–10), no data are available on
whether acute, short-term hyperglycemia further enhances
platelet activation. Indeed, several clues point to an impor-
tant role of hyperglycemic spikes in triggering ischemic
cardiovascular complications in T2DM (11–13), but no
definite information is available on the effector mechanisms
through which acute hyperglycemia may elicit arterial
thrombosis.
The present study was designed to evaluate, in experi-
mentally controlled conditions, whether acute, short-term,
hyperglycemia enhances platelet activation and especially
the activation induced by high shear stress, which is of
particular pathophysiologic relevance to platelet thrombus
formation at arterial sites of atherosclerotic stenosis (14–
17).
Role of high shear stress in the acute hyperglycemia-
induced platelet activation. Our results show that acute,
short-term hyperglycemia induces an increased activation of
platelets exposed to high shear stress in vitro or in vivo, with
a mechanism dependent on a raised plasma level of vWF.
Indeed, shear stress activation of platelets ex vivo—a pa-
rameter highly sensitive to the interaction between vWF
and platelets (24,25)—was clearly enhanced after 4 h of
hyperglycemia and was not changed after 4 h of euglycemia.
Moreover, platelet activation at a localized site of vessel wall
damage (i.e., that occurring during the platelet plug forma-
tion of the bleeding-time procedure in a condition of
average to high shear forces [19 to 60.8 dynes/cm2]) (32)
was increased after acute hyperglycemia but not after short-
term euglycemia.
High shear stress-induced platelet activation is strictly
dependent on plasma vWF (15,24,25), and we have shown
that short-term hyperglycemia induces a significant rise in
plasma vWF, whereas after 4 h of euglycemia, no changes in
vWF were observed. Urinary 11-dehydro-TxB2, an in vivo
index of platelet activation, also shows that short-term
hyperglycemia induces a spike in platelet activation in
diabetics, with subsequent rapid restoration to pre-
hyperglycemic conditions.
Because urinary excretion of 11-dehydro-TxB2 gives an
integrated view of platelet thromboxane A2 produced in a
given period, wherever in the circulation (33), it is conceiv-
able that upon hyperglycemia, platelets get activated by high
shear at localized sites of arterial stenosis, as a consequence
of raised circulating vWF, but to an extent not sufficient to
acutely modify the expression of P-selectin on platelets
recovered in venous blood.
On the other hand, platelet aggregation studied by
photometric aggregometry, typically a platelet function test
performed under conditions of low shear stress (34), or the
expression of P-selectin or LIMP on platelets circulating in
venous blood was unaffected by short-term hyperglycemia.
Interestingly, variations in plasma vWF correlated signif-
icantly with ex vivo shear stress–induced platelet activation,
with P-selectin expression on platelets undergoing in vivo
activation during hemostatic plug formation (bleeding
time), and with urinary excretion of 11-dehydro-TxB2—all
tests involving the exposure of platelets to high shear
conditions—whereas no correlations were evident between
vWF and P-selectin on platelets in venous blood or with
ADP-induced platelet aggregation in vitro—tests not in-
volving exposure of platelets to high shear stress.
Study limitations. The patients we studied were under
fairly good glycemic control, as indicated by their HbA1c
values, and it is conceivable that in patients with poorer
metabolic control, a stronger pre-existing in vivo platelet
activation could have been present. Whether or not acute
hyperglycemia would further enhance platelet activation in
these patients remains to be determined. In addition, the
intravenous glucose clamp technique does not fully mimic
the condition of post-prandial hyperglycemia, which in-
volves a concomitant rise in plasma triglycerides and oxi-
dants, and more. However, most of the studies linking acute
hyperglycemia to cardiovascular complications utilized the
oral glucose tolerance test (11,13), a rather artificial hyper-
glycemia as well.
The method we used for inducing acute hyperglycemia
implies the generation of hyperinsulinemia, which, on the
other hand, is common in the post-prandial condition of
T2DM (35). Hyperinsulinemia, per se, has been reported to
represent a cardiovascular risk factor (36,37), and this might
theoretically have confounded our results. However, the
present studies were well matched for hyperinsulinemia;
thus, the differences observed in terms of platelet function
may be entirely attributed to the different plasma glucose
rather than insulin concentrations.
Conclusions. Acute, short-term hyperglycemia in patients
with T2DM induces a transient hyper-reactivity of platelets
to high shear stress, and thus it may potentially contribute to
precipitating arterial thrombotic occlusion at stenotic sites.
This observation may be of special relevance for patients
with T2DM undergoing surgery or for those who are in the
early hours of an acute coronary event or in stress situations
typically associated with acute hyperglycemia (38), all of
which are conditions accompanied by an enhanced inci-
dence of cardiovascular events. Finally, platelet activation
induced by high shear stress is poorly sensitive to inhibition
by aspirin (39–41), and this might imply the use of
alternative therapeutic strategies in patients with T2DM,
with a special emphasis on those interventions able to
prevent shear stress–induced platelet activation.
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